Securities Registration: Employee Benefit Plan (s-8)
November 09 2017 - 5:22PM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on November 9, 2017.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
CHECKPOINT
THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
47-2568632
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address, including Zip Code, of Principal
Executive Offices)
Checkpoint Therapeutics, Inc. Amended
and Restated 2015 Incentive Plan
(Full title of the
plan)
|
|
Copy to:
|
James F. Oliviero
President and Chief Executive Officer
Checkpoint Therapeutics, Inc.
2 Gansevoort Street, 9
th
Floor
New York, New York 10014
(781) 652-4500
(Name, address and telephone
number of agent
for service)
|
|
Mark McElreath
Alston & Bird LLP
90 Park Avenue, 12
th
Floor
New York, NY 10016
(212) 210-9595
|
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large
accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act. (Check one):
Large accelerated filer
¨
Non-accelerated filer
x
|
|
Accelerated filer
¨
Smaller reporting company
¨
Emerging growth company
x
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act.
¨
CALCULATION OF REGISTRATION FEE
Title of securities
to be registered
|
|
Amount to
be registered
|
|
|
Proposed
maximum
offering price
per share
|
|
|
Proposed
maximum
aggregate
offering price
|
|
|
Amount of
registration fee
|
|
Common Stock, $0.0001 par value
|
|
|
3,000,000
|
(1)
|
|
$
|
5.97
|
(2)
|
|
$
|
17,910,000
|
(2)
|
|
$
|
2,229.80
|
|
|
(1)
|
Amount to be registered consists of an aggregate of 3,000,000
shares of Checkpoint Therapeutics, Inc. Common Stock, par value $0.0001 per share (the “Common Stock”), including
any additional shares that may become issuable in accordance with the adjustment and anti-dilution provisions of the Checkpoint
Therapeutics, Inc. Amended and Restated 2015 Incentive Plan.
|
|
(2)
|
Determined in accordance with Rule 457(h) under the Securities
Act of 1933, as amended, the registration fee calculation for these shares is based on the average of the high and low prices
of the Common Stock, reported on the Nasdaq Capital Market on November 7, 2017.
|
PART I
INFORMATION REQUIRED IN THE SECTION 10(a)
PROSPECTUS
(a) The
documents constituting Part I of this registration statement on Form S-8 (this “Registration Statement”) will be delivered
to participants in the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (the “Plan”) as specified
by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). These documents and the documents
incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute
a prospectus that meets the requirements of Section 10(a) of the Securities Act.
(b) Upon
written or oral request, Checkpoint Therapeutics, Inc. (the “Company”) will provide, without charge, the documents
incorporated by reference in Item 3 of Part II of this Registration Statement. The documents are incorporated by reference in
the Section 10(a) prospectus. The Company will also provide, without charge, upon written or oral request, other documents required
to be delivered to employees pursuant to Rule 428(b). Requests for the above mentioned information should be directed to Investor
Relations at
ir@checkpointtx.com
, or to James F. Oliviero, President and Chief Executive Officer, at the address and telephone
number on the cover page of this Registration Statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT
|
Item 3.
|
Incorporation of Documents by Reference.
|
The following documents,
filed with the Securities and Exchange Commission (the “Commission”) by the Company pursuant to the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:
|
(a)
|
The Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with
the Commission on March 17, 2017, and amended on March 21, 2017;
|
|
(b)
|
The Company’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2017, filed
on May 10, 2017, the quarter ended June 30, 2017, filed on August 9, 2017, and the quarter ended September 30, 2017, filed on November
3, 2017;
|
|
(c)
|
The Company’s Current Reports on Form 8-K, filed on January 6, 2017, June 20, 2017,
June 27,
2017, and October 5, 2017; and
|
|
(d)
|
The description of the Common Stock contained in the Form 10-12G filed with the Commission on July
11, 2016, pursuant to the Exchange Act, and any amendment or report filed for the purpose of further updating such description.
|
All reports and other
documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing
of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities that
remain unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the
date of filing of such documents.
Any statement contained
in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which
also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
|
Item 4.
|
Description of Securities.
|
Not applicable.
|
Item 5.
|
Interests of Named Experts and Counsel.
|
Not applicable.
|
Item 6.
|
Indemnification of Directors and Officers.
|
Under the General Corporation
Law of the State of Delaware (“DGCL”), a corporation may include provisions in its certificate of incorporation that
will relieve its directors of monetary liability for breaches of their fiduciary duty to the corporation, except under certain
circumstances, including a breach of the director’s duty of loyalty, acts or omissions of the director not in good faith
or which involve intentional misconduct or a knowing violation of law, the approval of an improper payment of a dividend or an
improper purchase by the corporation of stock or any transaction from which the director derived an improper personal benefit.
The Company’s Amended and Restated Certificate of Incorporation eliminates the personal liability of directors to the Company
or its stockholders for monetary damages for breach of fiduciary duty as a director with certain limited exceptions set forth in
the DGCL.
Section 145 of the
DGCL grants to corporations the power to indemnify each officer and director against liabilities and expenses incurred by reason
of the fact that he or she is or was an officer or director of the corporation if he or she acted in good faith and in a manner
he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The Company’s Amended and Restated
Certificate of Incorporation and Bylaws provide for indemnification of each officer and director of the Company to the fullest
extent permitted by the DGCL. Section 145 of the DGCL also empowers corporations to purchase and maintain insurance on behalf of
any person who is or was an officer or director of the corporation against liability asserted against or incurred by him in any
such capacity, whether or not the corporation would have the power to indemnify such officer or director against such liability
under the provisions of Section 145 of the DGCL.
|
Item 7.
|
Exemption from Registration Claimed.
|
Not applicable.
See the Exhibit Index,
which is incorporated herein by reference.
|
(a)
|
The Company hereby undertakes:
|
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement;
(iii) To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;
provided, however
,
that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information
required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the
Commission by the Company pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78
o
(d))
that are incorporated by reference in the registration statement;
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial
bona fide
offering thereof; and
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
the termination of the offering.
(b) The
undersigned Company hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the Company’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934)
that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(c) Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of
expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
(Signatures on following page)
SIGNATURES
The Registrant
.
Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the city of New York, state of New York, on this 9
th
day of November,
2017.
|
CHECKPOINT THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ James F. Oliviero
|
|
|
|
James F. Oliviero
|
|
|
|
President and Chief Executive Officer
|
|
POWER OF ATTORNEY
KNOW BY ALL MEN
BY THESE PRESENT,
that each person whose signature appears below constitutes and appoints James F. Oliviero, and each or any
one of them, as true and lawful attorneys-in-fact and agents, with full power of substitution, for him and in his name, place and
stead, in any and all capacities, to sign any amendments (including post-effective amendments) to this registration statement and
to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
hereby ratifying and confirming all that said attorney-in-fact, or their substitute or substitutes, may lawfully do or cause to
be done by virtue thereof.
Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the
dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
|
|
|
/s/ James F. Oliviero
|
|
Chief Executive Officer and President
|
|
November 9, 2017
|
James F. Oliviero
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ William Garrett Gray
|
|
Vice President, Finance and Accounting
|
|
November 9, 2017
|
William Garrett Gray
|
|
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Michael S. Weiss
|
|
Chairman of the Board
|
|
November 9, 2017
|
Michael S. Weiss
|
|
|
|
|
|
|
|
|
|
/s/ Lindsay A. Rosenwald, M.D.
|
|
Director
|
|
November 9, 2017
|
Lindsay A. Rosenwald, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Neil Herskowitz
|
|
Director
|
|
November 9, 2017
|
Neil Herskowitz
|
|
|
|
|
|
|
|
|
|
/s/ Barry Salzman
|
|
Director
|
|
November 9, 2017
|
Barry Salzman
|
|
|
|
|
|
|
|
|
|
/s/ Scott Boilen
|
|
Director
|
|
November 9, 2017
|
Scott Boilen
|
|
|
|
|
EXHIBIT INDEX
TO
REGISTRATION STATEMENT
ON FORM S-8
Exhibit Number
|
|
Description
|
|
4.1
|
|
Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., filed as Exhibit 3.1 to Form 10-12G filed on July 11, 2016 (File No. 000-55506) and incorporated herein by reference.
|
|
|
|
4.2
|
|
Certificate of Amendment to Certificate of Incorporation of Checkpoint Therapeutics, Inc., filed as Exhibit 3.2 to Form 10-12G filed on July 11, 2016 (File No. 000-55506) and incorporated herein by reference.
|
|
|
|
4.3
|
|
Bylaws of Checkpoint Therapeutics, Inc., filed as Exhibit 3.3 to Form 10-12G filed on July 11, 2016 (File No. 000-55506) and incorporated herein by reference.
|
|
|
|
5.1
|
|
Opinion of Alston & Bird LLP (filed herewith).
|
|
|
|
23.1
|
|
Consent of BDO USA, LLP, Independent Registered Public
Accounting Firm.
|
|
|
|
23.2
|
|
Consent of EisnerAmper LLP, Independent Registered
Public Accounting Firm.
|
|
|
|
23.3
|
|
Consent of Alston & Bird LLP (included in Exhibit 5.1).
|
|
|
|
24.1
|
|
Power of Attorney (included on signature page).
|
|
|
|
99.1
|
|
Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan, dated April 10, 2017, filed with Definitive Proxy Statement filed on April 28, 2017, and incorporated herein by reference.
|
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Apr 2023 to Apr 2024